Maraviroc: The first CCR5 antagonist for the treatment of HIV

Formulary

Volumn 42, Issue 10, 2007, Pages 601-608

  Girotto, Jennifer E ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CLARITHROMYCIN; DELAVIRDINE; EFAVIRENZ; ENZYME INHIBITOR; ETHINYLESTRADIOL; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LEVONORGESTREL; MARAVIROC; MIDAZOLAM; NEVIRAPINE; PLACEBO; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TENOFOVIR; TIPRANAVIR;

ADD ON THERAPY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACKACHE; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG SOLUBILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER TOXICITY; ORTHOSTATIC HYPOTENSION; QT PROLONGATION; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

EID: 35649011406     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Joint United Nations Programme on HIV/AIDS. AIDS Epidemic Update: December 2006. http://www.unaids.org/en/hiv_data/epi2006/default.asp. Accessed September 10, 2007.
2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A working group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov./guidelines/guidelinedetail.aspx? menuitem=guidelines&search=off&guidelineid=7&classid=1. Published October 10, 2006. Accessed September 10, 2007.
3. Selzentry [package insert]. New York, NY: Pfizer Inc; August 2007.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral Entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
5. Antiviral Drugs Advisory Committee (AVDAC) briefing document: Maraviroc tablets NDA 22-128. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4283b1- 01-pfizer.pdf. Published April 24, 2007. Accessed September 10, 2007.
6. NIAID-Division of AIDS HIV/OI/TB therapeutics database. http://chemdb2.niaid.nih.gov/struct_search/all/url_search.asp?aids_no=104834. Accessed September 10, 2007.
7. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170-1172.
8. Kuritzkes D. New agents and new paradigms: The complexity of CCRS inhibition. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 108.
9. Lewis M, Westby M, Smith-Burchnell C, Mori J, Whitcomb J, Perros M. A genotypic analysis of HIV-1 sequences from emerging resistant virus after in vitro serial passage with the CCR5 antagonist maraviroc (UK-427857). Presented at: Third European HIV Drug Resistance Workshop; March 30-April 1, 2005; Athens, Greece. Abstract 91.
10. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-2371.
11. Mori J, Mosley M, Lewis M, et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Antivir Ther. 2007;12:S12.
12. Wesfby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-4920.
13. Lewis M, Simpson P, Fransen S, et al. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. Antivir Ther. 2007;12:S65.
14. Abel S, van der Ryst E, Muirhead GJ, Rosario M, Edgington A, Weissgerber G. Pharmacokinetics of single and multiple oral doses of UK-427,857 - A novel CCR5 antagonist in healthy volunteers. Poster presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003. Boston, MA. Abstract 547.
15. Fätkenheuer G, Pozniak AL, Johnson M, et al. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist. Presented at: The XV International AIDS Conference, 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4489.
16. Russell D, Ridgway C, Taylor-Worth R, Weissgerber G, Tan Y, Muirhead G. Comparison of the pharmacokinetics of maraviroc (UK-427,857) in healthy Asian and Caucasian subjects. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada. Abstract 41.
17. Walker DK, Abel S, Comby P, et al. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33:587-595.
18. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother. 2005;49:4721-4732.
19. Abel S, Russell D, Ridgway C, Medhurts C, Weissgerber G, Muirhead G. Effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Poster presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy. Poster 5.8.
20. Mayer H, van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiretrovirai-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. Presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0215.
21. van der Ryst E, Mayer H, Goodrich JM, et al. Selective suppression of R5 HIV-1 by the novel CCR5 antagonist maraviroc (MVC) is associated with maintenance of CD4 counts in antiretroviral-experienced patients (pts) infected with dual/mixed tropic (D/M) HIV-1. Presented at: Eighth International Congress on Drug Therapy in HIV Infection; November 12-16, 2006; Glasgow, UK. Abstract 286.
22. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104bLB.
23. Nelson M, Fätkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 104aLB.
24. Gulick R, van der Ryst E, Lampiris H, et al. Efficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007. Sydney, Australia. Abstract WEPEB116LB.
25. van der Ryst E, Cooper D, Konourina I, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of MOTIVATE 1 and 2 studies. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB115LB.
26. Saag M, Ive P, Heera J, et al. A multicenter, randomized, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients with R5 HIV 1: Week 48 results of the MERIT study. Presented at: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS104.
27. Davis J, Hackman F, Sudworth D, Weissgerber G. A single dose study to investigate the effect of the CCR5 antagonist maraviroc (UK-427,857) on the QTc interval in healthy subjects. Poster presented at: The XV International AIDS Conference, 2004; July 11-16,2004; Bangkok, Thailand. Poster 3.5.
28. Russell D, Weissgerber G, Wooldridge C, Ridgway C, Abel S, Muirhead G. Investigation into the haemodynamic effects of oral maraviroc (UK-427,857) in healthy volunteers. Poster presented at: 10th European AIDS Conference/EACS; November 17-20, 2005; Dublin, Ireland. Abstract LBPE4.1/10.
29. Abel S, Russell D, Ridgway C, Muirhead G. Overview of the drug-drug interaction data for maraviroc (UK-427,857). Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada. Abstract 76.
30. Hyland R, Jones B, Muirhead G. In vitro assessment of the CYP-based drug-drug interaction potential of UK-427,857. Poster presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy. Poster 5.9.
31. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427,857, in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy. Paper 5.4.
32. Muirhead G, Russell D, Abel S, et al. An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Presented at: Seventh International Congress on Drug Therapy in HIV Infection; November 14-17, 2004; Glasgow, UK. Abstract P282.
33. Muirhead G, Ridgway C, Leahy D, Mills C, van der Merwe R, Russell D. A study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Presented at: Seventh International Congress on Drug Therapy in HIV Infection; November 14-17, 2004; Glasgow, UK. Abstract P284.
34. Muirhead G, Abel S, Russell D, et al. An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Presented at: Seventh International Congress on Drug Therapy in HIV Infection; November 14-17, 2004; Glasgow, UK. Abstract P283.
35. Abel S, Taylor-Worth R, Ridgway C, Weissgerber G, Kraft M. Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK 427,857) in healthy volunteers. Poster presented at: 10th European AIDS Conference/EACS; November 17-20, 2005; Dublin, Ireland. Abstract LBPE4.3/15.
36. Muirhead G, Pozniak A, Boffito M, et al. A novel probe drug interaction study to investigate the effect of selected ARV combinations on the pharmacokinetics of a single oral dose of maraviroc (UK-427,857) in HTV+ve subjects. Poster presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada. Poster 2.19.
37. Muirhead G, Abel S, Hackman F, Whitlock L, van der Merwe R, Russell D. The effect of maraviroc (UK-427,857) on the pharmacokinetics of 3TC/AZT (combivir) in healthy subjects. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec, Canada. Poster 2.23.
38. Abel S, Whitlock L, Ridgway C, Saifulanwar A, Bakhtyari A, Russell D. Effect of UK-427,857, on the pharmacokinetics of oral contraceptive steroids, and the pharmacokinetics of UK-427,857 in healthy young women. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago, IL. Abstract A-1619.
39. Abel S, Russell D, Ridgway C, Medhurst C, Whitlock L, Weissgerber G, Muirhead G. Effect of CCR5 antagonist UK-427,857 on the pharmacokinetics of CYP3A4 substrates in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy. Poster 5.7.